A 31-year-old male with bipolar disorder comes to the physician because of erectile dysfunction for the past month. He cannot maintain an erection during intercourse and rarely wakes up with an erection. He says he is happy in his current relationship, but admits to decreased desire for sex and feeling embarrassed about his sexual performance. He sustained a lumbar vertebral injury one year ago following a motor vehicle accident. He takes medication for his bipolar disorder but does not remember the name. Physical examination shows testicular atrophy with otherwise normal genitalia. Which of the following is the most likely cause of this patient's symptoms?
Q622
A 23-year-old man comes to the emergency department because of a rash on his neck and back for the past 6 hours. He says that he first noticed some reddening of the skin on his back the previous evening, which turned into a blistering, red rash overnight. He went surfing the previous day and spent 5 hours at the beach. He reports having applied at least 1 oz of water-resistant SPF 30 sunscreen 30 minutes before leaving his home. His vitals are within normal limits. Physical examination shows erythema of the skin over the upper back and dorsum of the neck, with 3 vesicles filled with clear fluid. The affected area is edematous and tender to touch. Which of the following recommendations is most appropriate to prevent a recurrence of this patient's symptoms in the future?
Q623
A 58-year-old woman presents to the office after receiving a bone mineral density screening test result with a T score of -4.1 and a Z score of -3.8. She is diagnosed with osteoporosis. A review of her medical history reveals that she has taken estrogen-containing oral contraceptive pills from the age of 20 to 30. She suffered from heartburn from the age of 45 and took lansoprazole and ranitidine often for her symptoms. She also was on lithium for 2 years after being diagnosed with bipolar disorder at the age of 54. Last year she was diagnosed with congestive heart failure and was started on low dose hydrochlorothiazide. Which of her medications most likely contributed to the development of her osteoporosis?
Q624
A 37-year-old woman undergoes diagnostic laparoscopy under general anesthesia for evaluation of chronic pelvic pain. Postoperatively, the patient requires prolonged intubation. Neostigmine is administered. Results of acceleromyography during train-of-four ulnar nerve stimulation are shown. Which of the following drugs is most likely to have been used intraoperatively in this patient?
Q625
A 56-year-old man comes to the physician because of a painless blistering rash on his hands, forearms, and face for 2 weeks. The rash is not itchy and seems to get worse in the sunlight. He has also noticed that his urine is darker than usual. His aunt and sister have a history of similar skin lesions. Examination of the skin shows multiple fluid-filled blisters and oozing erosions on the forearms, dorsal side of both hands, and forehead. There are areas of hyperpigmented scarring and patches of bald skin along the sides of the blisters. Which of the following is the most appropriate pharmacotherapy to treat this patient's condition?
Q626
A 57-year-old man presents to his family physician for a checkup. He has had type 2 diabetes mellitus for 13 years, for which he has been taking metformin and vildagliptin. He has smoked 10–15 cigarettes daily for 29 years. Family history is irrelevant. Vital signs include: temperature 36.6°C (97.8°F), blood pressure 152/87 mm Hg and pulse 88/min. Examination reveals moderate abdominal obesity with a body mass index of 32 kg/m². The remainder of the examination is unremarkable. His fasting lipid profile is shown:
Total cholesterol (TC) 280 mg/dL
Low-density lipoprotein (LDL)-cholesterol 210 mg/dL
High-density lipoprotein (HDL)-cholesterol 40 mg/dL
Triglycerides (TGs) 230 mg/dL
Which of the following is the mechanism of action of the best initial therapy for this patient?
Q627
A 56-year-old man presents for a follow-up regarding his management for type 2 diabetes mellitus (DM). He was diagnosed with type 2 DM about 7 years ago and was recently started on insulin therapy because oral agents were insufficient to control his glucose levels. He is currently following a regimen combining insulin lispro and neutral protamine Hagedorn (NPH) insulin. He is taking insulin lispro 3 times a day before meals and NPH insulin once in the morning. He has been on this regimen for about 2 months. He says that his glucose reading at night averages around 200 mg/dL and remains close to 180 mg/dL before his shot of NPH in the morning. The readings during the rest of the day range between 100–120 mg/dL. The patient denies any changes in vision or tingling or numbness in his hands or feet. His latest HbA1C level was 6.2%. Which of the following adjustments to his insulin regimen would be most effective in helping this patient achieve better glycemic control?
Q628
A 52-year-old man who was recently hospitalized with a pulmonary embolism is put on an unfractionated heparin drip as a bridge to chronic warfarin therapy. During morning rounds, he is found to have diffuse bruising despite minimal trauma, and his heparin infusion rate is found to be faster than prescribed. A coagulation panel is obtained, which shows a aPTT of 130 seconds (therapeutic 70-120 seconds), and the decision is made to reverse the effects of heparin. Which of the following would most likely be administered in order to do this?
Q629
Background: Beta-blockers reduce mortality in patients who have chronic heart failure, systolic dysfunction, and are on background treatment with diuretics and angiotensin-converting enzyme inhibitors. We aimed to compare the effects of carvedilol and metoprolol on clinical outcome.
Methods: In a multicenter, double-blind, and randomized parallel group trial, we assigned 1,511 patients with chronic heart failure to treatment with carvedilol (target dose 25 mg twice daily) and 1,518 to metoprolol (metoprolol tartrate, target dose 50 mg twice daily). Patients were required to have chronic heart failure (NYHA II-IV), previous admission for a cardiovascular reason, an ejection fraction of less than 0.35, and to have been treated optimally with diuretics and angiotensin-converting enzyme inhibitors unless not tolerated. The primary endpoints were all-cause mortality, the composite endpoint of all-cause mortality, or all-cause admission. Analysis was done by intention to treat
Findings: The mean study duration was 58 months (SD 6). The mean ejection fraction was 0.26 (0.07) and the mean age was 62 years (11). The all-cause mortality was 34% (512 of 1,511) for carvedilol and 40% (600 of 1,518) for metoprolol (hazard ratio 0.83 [95% CI 0.74-0.93], p = 0.0017). The reduction of all-cause mortality was consistent across predefined subgroups. Incidence of side effects and drug withdrawals did not differ by much between the 2 study groups.
Which of the following represents the number of patients needed to treat to save one life?
Q630
A 56-year-old man presents with sudden-onset severe eye pain and blurred vision. He says the symptoms onset an hour ago and his vision has progressively worsened. Physical examination reveals a cloudy cornea and decreased visual acuity. Timolol is administered into the eyes to treat this patient’s symptoms. Which of the following best describes the mechanism of action of this drug in the treatment of this patient’s condition?
Autonomic/CV Drugs US Medical PG Practice Questions and MCQs
Question 621: A 31-year-old male with bipolar disorder comes to the physician because of erectile dysfunction for the past month. He cannot maintain an erection during intercourse and rarely wakes up with an erection. He says he is happy in his current relationship, but admits to decreased desire for sex and feeling embarrassed about his sexual performance. He sustained a lumbar vertebral injury one year ago following a motor vehicle accident. He takes medication for his bipolar disorder but does not remember the name. Physical examination shows testicular atrophy with otherwise normal genitalia. Which of the following is the most likely cause of this patient's symptoms?
A. Psychologic stressors
B. Microvascular disease
C. Peripheral nerve injury
D. Peyronie disease
E. Decreased testosterone levels (Correct Answer)
Explanation: ***Decreased testosterone levels***
- This patient's **testicular atrophy** is a strong indicator of primary testicular failure leading to **hypogonadism** and decreased testosterone.
- Decreased testosterone causes **erectile dysfunction**, reduced libido and morning erections, all consistent with the patient's symptoms.
- The most likely cause of testicular atrophy in this patient is **medication-induced hypogonadism** from his bipolar disorder treatment—particularly **valproate** (which causes testicular atrophy and suppresses spermatogenesis) or certain **antipsychotic medications**.
- Regardless of the underlying etiology of testicular atrophy, the **proximate cause** of his erectile dysfunction is the resulting **decreased testosterone levels**.
*Psychologic stressors*
- While psychological factors can cause erectile dysfunction, the presence of **testicular atrophy** points to a clear organic cause.
- His reported happiness in the relationship also makes primary psychological etiology less likely, though performance anxiety could be secondary.
*Microvascular disease*
- Microvascular disease, often associated with **diabetes** or **hypertension**, can cause erectile dysfunction due to impaired blood flow.
- However, it does not explain the **testicular atrophy** observed in this patient.
*Peripheral nerve injury*
- A lumbar vertebral injury could potentially cause **neuropathic erectile dysfunction** if nerves innervating the penis were damaged.
- This typically does not lead to **testicular atrophy**, making it a less likely primary cause given the physical exam findings.
*Peyronie disease*
- Peyronie disease involves the formation of **fibrous plaques** in the penile tunica albuginea, leading to penile curvature and painful erections.
- It does not cause **testicular atrophy** or decreased libido, and no penile curvature is mentioned.
Question 622: A 23-year-old man comes to the emergency department because of a rash on his neck and back for the past 6 hours. He says that he first noticed some reddening of the skin on his back the previous evening, which turned into a blistering, red rash overnight. He went surfing the previous day and spent 5 hours at the beach. He reports having applied at least 1 oz of water-resistant SPF 30 sunscreen 30 minutes before leaving his home. His vitals are within normal limits. Physical examination shows erythema of the skin over the upper back and dorsum of the neck, with 3 vesicles filled with clear fluid. The affected area is edematous and tender to touch. Which of the following recommendations is most appropriate to prevent a recurrence of this patient's symptoms in the future?
A. Use waterproof sunscreen
B. Reapply sunscreen after water exposure (Correct Answer)
C. Use SPF 50 sunscreen
D. Apply at least 3 oz of sunscreen
E. Apply sunscreen directly before getting into water
Explanation: ***Reapply sunscreen after water exposure***
- The patient spent 5 hours at the beach and went surfing, indicating significant **water exposure**. Even **water-resistant sunscreen** eventually loses its effectiveness, especially after prolonged water immersion, necessitating reapplication.
- The presence of **blistering and erythema with vesicles** indicates a **second-degree sunburn**, which occurred despite initial sunscreen application, highlighting the need for reapplication after activities involving sweat or water.
*Use waterproof sunscreen*
- The patient already used **water-resistant sunscreen**, which provides some protection in water, but its effectiveness is not indefinite; "waterproof" implies even longer resistance (*80 minutes* vs. *40 minutes* for water-resistant), but still requires reapplication after certain time or activities.
- Emphasizing "waterproof" over "reapplication" does not address the core issue of the sunscreen eventually washing off or degrading with prolonged water exposure and friction.
*Use SPF 50 sunscreen*
- While a higher **SPF (e.g., 50 vs. 30)** offers slightly more protection, the primary issue here is likely the **duration of protection and water exposure**, not merely the initial SPF factor.
- SPF 30 blocks about 97% of UVB rays, while SPF 50 blocks 98%, a marginal difference that does not negate the need for reapplication.
*Apply at least 3 oz of sunscreen*
- The patient reported applying "at least 1 oz" of SPF 30 sunscreen, which is often considered adequate for a single full-body application for an average adult (the recommended amount is about 1 oz for the entire body).
- While more sunscreen can provide better coverage, the problem is most likely related to the **duration of efficacy** and **water exposure**, not the initial quantity applied if it was sufficient.
*Apply sunscreen directly before getting into water*
- Sunscreen needs time to bind to the skin and become effective. Applying it "directly before" getting into water (as opposed to 15-30 minutes before exposure) can reduce its protective capacity, as it may wash off before it fully penetrates the skin.
- The patient applied sunscreen 30 minutes before leaving home, which is the recommended time for optimal absorption and protection. His sunburn indicates an issue with **maintenance of protection**, not initial application timing.
Question 623: A 58-year-old woman presents to the office after receiving a bone mineral density screening test result with a T score of -4.1 and a Z score of -3.8. She is diagnosed with osteoporosis. A review of her medical history reveals that she has taken estrogen-containing oral contraceptive pills from the age of 20 to 30. She suffered from heartburn from the age of 45 and took lansoprazole and ranitidine often for her symptoms. She also was on lithium for 2 years after being diagnosed with bipolar disorder at the age of 54. Last year she was diagnosed with congestive heart failure and was started on low dose hydrochlorothiazide. Which of her medications most likely contributed to the development of her osteoporosis?
A. Ranitidine
B. Lansoprazole (Correct Answer)
C. Hydrochlorothiazide
D. Lithium
E. Estrogen
Explanation: ***Lansoprazole***
- **Proton pump inhibitors (PPIs)** like lansoprazole reduce gastric acid production, which can impair the absorption of **calcium** and **magnesium**, leading to a negative impact on bone mineral density with long-term use.
- Chronic use of PPIs has been associated with an increased risk of **osteoporosis** and **fractures**, especially in older adults.
*Ranitidine*
- Ranitidine is a **H2-receptor blocker**, which also reduces stomach acid but acts via a different mechanism than PPIs. It is generally not as strongly linked to osteoporosis as PPIs.
- While decreased gastric acid can affect nutrient absorption, the evidence for ranitidine directly causing osteoporosis is significantly weaker compared to PPIs.
*Hydrochlorothiazide*
- **Thiazide diuretics** like hydrochlorothiazide are known to **decrease urinary calcium excretion**, which can actually have a protective effect on bone mineral density, or at least be neutral.
- Therefore, hydrochlorothiazide is unlikely to contribute to or worsen osteoporosis; it may even be beneficial for bone health.
*Lithium*
- Lithium typically does not have a direct adverse effect on bone mineral density; its primary effects are on the **central nervous system**.
- Some studies have suggested potential complex effects on bone metabolism, but it is not a recognized direct cause of osteoporosis.
*Estrogen*
- **Estrogen** generally has a **protective effect on bone health** by inhibiting bone resorption.
- The past use of estrogen-containing oral contraceptive pills would have been protective during that period and does not contribute to current osteoporosis; rather, post-menopausal estrogen deficiency is a major risk factor for osteoporosis.
Question 624: A 37-year-old woman undergoes diagnostic laparoscopy under general anesthesia for evaluation of chronic pelvic pain. Postoperatively, the patient requires prolonged intubation. Neostigmine is administered. Results of acceleromyography during train-of-four ulnar nerve stimulation are shown. Which of the following drugs is most likely to have been used intraoperatively in this patient?
A. Tizanidine
B. Clonazepam
C. Ropivacaine
D. Succinylcholine (Correct Answer)
E. Rocuronium
Explanation: ***Succinylcholine***
- The scenario describes a patient requiring **prolonged intubation** and the administration of **neostigmine** for neuromuscular blockade reversal, along with **acceleromyography** results.
- This constellation points to the use of a **depolarizing neuromuscular blocker** like succinylcholine, especially if the patient has atypical plasma **pseudocholinesterase activity**, leading to prolonged paralysis.
*Tizanidine*
- Tizanidine is an **alpha-2 adrenergic agonist** used as a centrally acting muscle relaxant.
- It does not cause neuromuscular blockade that requires reversal with **neostigmine** or monitoring with **acceleromyography** during general anesthesia.
*Clonazepam*
- Clonazepam is a **benzodiazepine** used as an anxiolytic and anticonvulsant.
- It acts on **GABA-A receptors** in the central nervous system and does not directly affect the neuromuscular junction.
*Ropivacaine*
- Ropivacaine is a **local anesthetic** that blocks voltage-gated sodium channels in nerve membranes.
- It is used for regional anesthesia or epidurals and does not cause generalized neuromuscular paralysis requiring such reversal.
*Rocuronium*
- Rocuronium is a **nondepolarizing neuromuscular blocker**, which would also cause neuromuscular blockade.
- However, the description of prolonged intubation followed by neostigmine (an anticholinesterase) could indicate **phase II block** from rocuronium, but the phrasing more strongly suggests **succinylcholine** given the potential for prolonged action due to pseudocholinesterase deficiency.
Question 625: A 56-year-old man comes to the physician because of a painless blistering rash on his hands, forearms, and face for 2 weeks. The rash is not itchy and seems to get worse in the sunlight. He has also noticed that his urine is darker than usual. His aunt and sister have a history of similar skin lesions. Examination of the skin shows multiple fluid-filled blisters and oozing erosions on the forearms, dorsal side of both hands, and forehead. There are areas of hyperpigmented scarring and patches of bald skin along the sides of the blisters. Which of the following is the most appropriate pharmacotherapy to treat this patient's condition?
A. Phlebotomy
B. Hemin
C. Acyclovir
D. Low-dose hydroxychloroquine (Correct Answer)
E. Prednisone
Explanation: ***Low-dose hydroxychloroquine***
- This patient presents with symptoms highly suggestive of **porphyria cutanea tarda (PCT)**, including **painless blistering rash** on sun-exposed areas, worsening with sunlight, **hyperpigmented scarring**, and **dark urine**.
- **Low-dose hydroxychloroquine** is the most appropriate **pharmacotherapy** for PCT. It works by forming a complex with excess porphyrins which facilitates their excretion and helps to alleviate cutaneous symptoms.
- As an antimalarial and immunomodulatory agent, hydroxychloroquine provides effective symptomatic relief in PCT.
*Phlebotomy*
- **Phlebotomy** is actually a **primary treatment for PCT**, aiming to reduce elevated iron stores, which are often a contributing factor to the disease.
- However, phlebotomy is a **procedure, not a pharmacotherapy**. Since the question specifically asks for pharmacotherapy (drug treatment), this is not the correct answer despite being an effective treatment modality for PCT.
*Hemin*
- **Hemin** is used to treat **acute hepatic porphyrias** (e.g., acute intermittent porphyria), not porphyria cutanea tarda.
- It works by suppressing hepatic delta-aminolevulinic acid (ALA) synthase activity, thereby reducing the overproduction of neurotoxic heme precursors characteristic of acute porphyrias.
- PCT is a **cutaneous porphyria**, not an acute hepatic porphyria, making hemin inappropriate.
*Acyclovir*
- **Acyclovir** is an **antiviral medication** used to treat herpes simplex virus or varicella-zoster virus infections.
- The patient's symptoms (photosensitive blistering, dark urine, family history) are characteristic of PCT, not a viral infection, making acyclovir inappropriate.
*Prednisone*
- **Prednisone** is a **corticosteroid** with anti-inflammatory and immunosuppressive properties, often used for autoimmune blistering diseases.
- It is **not indicated** for PCT and could potentially worsen the condition by affecting liver enzyme activity or exacerbating photosensitivity.
Question 626: A 57-year-old man presents to his family physician for a checkup. He has had type 2 diabetes mellitus for 13 years, for which he has been taking metformin and vildagliptin. He has smoked 10–15 cigarettes daily for 29 years. Family history is irrelevant. Vital signs include: temperature 36.6°C (97.8°F), blood pressure 152/87 mm Hg and pulse 88/min. Examination reveals moderate abdominal obesity with a body mass index of 32 kg/m². The remainder of the examination is unremarkable. His fasting lipid profile is shown:
Total cholesterol (TC) 280 mg/dL
Low-density lipoprotein (LDL)-cholesterol 210 mg/dL
High-density lipoprotein (HDL)-cholesterol 40 mg/dL
Triglycerides (TGs) 230 mg/dL
Which of the following is the mechanism of action of the best initial therapy for this patient?
A. Activation of PPAR-alpha
B. Inhibition of cholesterol absorption
C. Bile acid sequestration
D. Inhibition of cholesterol synthesis (Correct Answer)
E. Inhibition of adipose tissue lipolysis
Explanation: ***Inhibition of cholesterol synthesis***
- This patient has multiple risk factors for cardiovascular disease including **type 2 diabetes**, **hypertension**, **smoking**, and significantly **elevated LDL-cholesterol (210 mg/dL)**, making him a candidate for high-intensity statin therapy.
- **Statins** (HMG-CoA reductase inhibitors) are the first-line therapy for such patients as they significantly reduce cardiovascular events by **inhibiting the rate-limiting step in cholesterol synthesis** in the liver.
*Activation of PPAR-alpha*
- This is the mechanism of action of **fibrates** (e.g., fenofibrate, gemfibrozil), which are primarily used to **lower triglycerides** and raise HDL-cholesterol.
- While this patient has elevated triglycerides, his primary lipid abnormality and cardiovascular risk comes from his high LDL-cholesterol, making statins the better initial choice.
*Inhibition of cholesterol absorption*
- This describes the mechanism of action of **ezetimibe**, which selectively inhibits cholesterol absorption at the brush border of the small intestine.
- Ezetimibe is typically used as an add-on therapy if statins alone are insufficient to reach LDL-C goals, or if a patient is statin-intolerant, not as a monotherapy for high-risk patients.
*Bile acid sequestration*
- This is the mechanism of **bile acid resins** (e.g., cholestyramine, colestipol, colesevelam), which bind bile acids in the intestine, preventing their reabsorption and increasing their excretion.
- This leads to increased hepatic synthesis of bile acids from cholesterol, thereby upregulating LDL receptors and lowering LDL-cholesterol, but they are less potent than statins and can cause gastrointestinal side effects.
*Inhibition of adipose tissue lipolysis*
- This is the mechanism of action of **niacin (nicotinic acid)**, which reduces the synthesis of VLDL and LDL by inhibiting lipolysis in adipose tissue.
- Niacin can improve all lipid parameters but is often associated with significant side effects (e.g., flushing, insulin resistance) and has not consistently shown cardiovascular benefit beyond statins in recent trials, making it a less preferred initial therapy.
Question 627: A 56-year-old man presents for a follow-up regarding his management for type 2 diabetes mellitus (DM). He was diagnosed with type 2 DM about 7 years ago and was recently started on insulin therapy because oral agents were insufficient to control his glucose levels. He is currently following a regimen combining insulin lispro and neutral protamine Hagedorn (NPH) insulin. He is taking insulin lispro 3 times a day before meals and NPH insulin once in the morning. He has been on this regimen for about 2 months. He says that his glucose reading at night averages around 200 mg/dL and remains close to 180 mg/dL before his shot of NPH in the morning. The readings during the rest of the day range between 100–120 mg/dL. The patient denies any changes in vision or tingling or numbness in his hands or feet. His latest HbA1C level was 6.2%. Which of the following adjustments to his insulin regimen would be most effective in helping this patient achieve better glycemic control?
A. Add another dose of insulin lispro in the evening.
B. Reduce a dose of insulin lispro.
C. Replace lispro with insulin aspart.
D. Add insulin glargine to the current regimen.
E. Add another dose of NPH in the evening. (Correct Answer)
Explanation: ***Add another dose of NPH in the evening.***
- The patient has persistently elevated **nighttime** and **pre-morning glucose levels** (200 mg/dL and 180 mg/dL, respectively), while daytime levels are well-controlled. This indicates insufficient **basal insulin coverage** overnight.
- Adding a dose of **intermediate-acting NPH insulin** in the evening would provide longer-acting basal insulin to cover the overnight period and address the high morning fasting glucose.
*Add another dose of insulin lispro in the evening.*
- Insulin lispro is a **rapid-acting insulin** primarily used to cover post-prandial glucose spikes. Adding another dose would primarily affect post-dinner glucose, not the sustained overnight hyperglycemia.
- While it might slightly lower evening glucose, its short duration of action would not adequately address the **pre-morning hyperglycemia**.
*Reduce a dose of insulin lispro.*
- The patient's **daytime glucose levels (100–120 mg/dL)** are well-controlled, suggesting that the current lispro doses are appropriate for meal coverage.
- Reducing lispro could lead to **post-prandial hyperglycemia** during the day, worsening overall control.
*Replace lispro with insulin aspart.*
- Both insulin lispro and insulin aspart are **rapid-acting insulins** with very similar pharmacokinetics and duration of action.
- Replacing one with the other would likely not significantly alter the glycemic profile, as the problem lies with **basal insulin coverage**, not rapid-acting insulin.
*Add insulin glargine to the current regimen.*
- While **insulin glargine** is a **long-acting basal insulin** and could address the overnight hyperglycemia, the patient is already on NPH as his basal insulin.
- The simpler and more direct adjustment would be to optimize the **existing NPH regimen** by adding an evening dose, rather than introducing a new type of basal insulin, which might complicate the regimen further or be less cost-effective.
Question 628: A 52-year-old man who was recently hospitalized with a pulmonary embolism is put on an unfractionated heparin drip as a bridge to chronic warfarin therapy. During morning rounds, he is found to have diffuse bruising despite minimal trauma, and his heparin infusion rate is found to be faster than prescribed. A coagulation panel is obtained, which shows a aPTT of 130 seconds (therapeutic 70-120 seconds), and the decision is made to reverse the effects of heparin. Which of the following would most likely be administered in order to do this?
A. Vitamin K
B. Fresh frozen plasma
C. Protamine sulfate (Correct Answer)
D. Platelets
E. Aminocaproic acid
Explanation: ***Correct: Protamine sulfate***
- **Specific reversal agent for heparin** via ionic binding (positively charged protamine neutralizes negatively charged heparin)
- Rapidly reverses anticoagulant effects within minutes
- Dose: 1 mg protamine per 100 units of heparin (titrated based on time since last dose)
- **Indicated for heparin overdose** with bleeding or need for urgent reversal
*Incorrect: Vitamin K*
- Reverses **warfarin**, not heparin
- Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X)
- Takes hours to work (requires synthesis of new clotting factors)
*Incorrect: Fresh frozen plasma*
- Contains clotting factors for **warfarin reversal** or coagulopathy from factor deficiency
- Not specific for heparin overdose
- Would be used if protamine fails or for complex coagulopathy
*Incorrect: Platelets*
- Used for thrombocytopenia or platelet dysfunction
- Does not reverse anticoagulant effects of heparin
- This patient has normal platelet function; issue is excessive anticoagulation
*Incorrect: Aminocaproic acid*
- Antifibrinolytic agent that inhibits plasminogen activation
- Used for hyperfibrinolysis (e.g., after thrombolytic therapy)
- Does not reverse heparin's effect on the coagulation cascade
Question 629: Background: Beta-blockers reduce mortality in patients who have chronic heart failure, systolic dysfunction, and are on background treatment with diuretics and angiotensin-converting enzyme inhibitors. We aimed to compare the effects of carvedilol and metoprolol on clinical outcome.
Methods: In a multicenter, double-blind, and randomized parallel group trial, we assigned 1,511 patients with chronic heart failure to treatment with carvedilol (target dose 25 mg twice daily) and 1,518 to metoprolol (metoprolol tartrate, target dose 50 mg twice daily). Patients were required to have chronic heart failure (NYHA II-IV), previous admission for a cardiovascular reason, an ejection fraction of less than 0.35, and to have been treated optimally with diuretics and angiotensin-converting enzyme inhibitors unless not tolerated. The primary endpoints were all-cause mortality, the composite endpoint of all-cause mortality, or all-cause admission. Analysis was done by intention to treat
Findings: The mean study duration was 58 months (SD 6). The mean ejection fraction was 0.26 (0.07) and the mean age was 62 years (11). The all-cause mortality was 34% (512 of 1,511) for carvedilol and 40% (600 of 1,518) for metoprolol (hazard ratio 0.83 [95% CI 0.74-0.93], p = 0.0017). The reduction of all-cause mortality was consistent across predefined subgroups. Incidence of side effects and drug withdrawals did not differ by much between the 2 study groups.
Which of the following represents the number of patients needed to treat to save one life?
A. 1/(34 - 40)
B. 1/0.83
C. 1/(0.40 - 0.34) (Correct Answer)
D. 1/(0.34 - 0.40)
E. 1/(40 - 34)
Explanation: ***1/(0.40 - 0.34)***
- The **number needed to treat (NNT)** is calculated as **1 / Absolute Risk Reduction (ARR)**.
- In this study, the mortality rate for carvedilol was 34% (0.34) and for metoprolol was 40% (0.40), so ARR = 0.40 - 0.34.
*1/(34 - 40)*
- This calculation uses raw percentages rather than **proportions**, and the subtraction order would result in a negative number, which is incorrect for NNT.
- The NNT is always a positive value, representing the number of patients to treat to prevent one adverse event.
*1/0.83*
- **0.83 represents the hazard ratio**, not the absolute risk reduction.
- The hazard ratio indicates the relative risk of an event in one group compared to another, not the difference in event rates needed for NNT.
*1/(0.34 - 0.40)*
- While using proportions, the **order of subtraction is incorrect**, yielding a negative value.
- The ARR should be the **risk in the control group minus the risk in the experimental group** to reflect the benefit of the intervention.
*1/(40 - 34)*
- This uses raw percentages instead of **proportions (decimal form)**, and while the result would be positive, it's conventional and more precise to use proportions in NNT calculations.
- Though numerically similar to the correct answer for the difference, using percentages directly for risk calculation can be less accurate in other contexts.
Question 630: A 56-year-old man presents with sudden-onset severe eye pain and blurred vision. He says the symptoms onset an hour ago and his vision has progressively worsened. Physical examination reveals a cloudy cornea and decreased visual acuity. Timolol is administered into the eyes to treat this patient’s symptoms. Which of the following best describes the mechanism of action of this drug in the treatment of this patient’s condition?
A. It decreases the production of aqueous humor by decreasing levels of bicarbonate through a cAMP-mediated pathway
B. It leads to opening of the trabecular meshwork
C. Increased outflow via dilatation of the uveoscleral veins
D. It suppresses the ciliary epithelium from producing aqueous humor (Correct Answer)
E. It increases the transit of aqueous humor into the vitreous humor for absorption into the choroid
Explanation: ***It suppresses the ciliary epithelium from producing aqueous humor***
- The patient's symptoms (sudden-onset severe **eye pain**, **blurred vision**, **cloudy cornea**, and **decreased visual acuity**) are classic for **acute angle-closure glaucoma**.
- **Timolol** is a **beta-blocker** that reduces intraocular pressure by **decreasing the production of aqueous humor** by the **ciliary epithelium**.
*It decreases the production of aqueous humor by decreasing levels of bicarbonate through a cAMP-mediated pathway*
- This mechanism describes **carbonic anhydrase inhibitors** (e.g., dorzolamide, acetazolamide), which decrease aqueous humor production by inhibiting the enzyme responsible for bicarbonate formation in the ciliary body.
- While carbonic anhydrase inhibitors can be used in glaucoma, this is not the mechanism of action for **timolol**.
*It leads to opening of the trabecular meshwork*
- Medications that increase outflow through the **trabecular meshwork** include **cholinergic agonists** (e.g., pilocarpine), which act by causing miosis and pulling on the scleral spur to open the meshwork.
- This is not the primary mechanism of action of **timolol**.
*Increased outflow via dilatation of the uveoscleral veins*
- Medications like **prostaglandin analogs** (e.g., latanoprost) increase uveoscleral outflow, but they do so by mechanisms involving remodeling of the extracellular matrix of the ciliary body and not directly dilating uveoscleral veins.
- **Timolol** primarily affects aqueous humor production, not outflow via this pathway.
*It increases the transit of aqueous humor into the vitreous humor for absorption into the choroid*
- The vitreous humor is a gel-like substance primarily for structural support and is not a major pathway for aqueous humor absorption or outflow.
- The primary outflow pathways for aqueous humor are the **trabecular meshwork** and the **uveoscleral pathway**.